Design of dose escalation studies and primary statistician for programs in oncology early development.Development of decision making frameworks for moving from early to pivotal studies.Development of standard eCRFs.

• Biomarker discovery and validation for Ipafricept, Vantictumab, and Tarextumab in breast, pancreatic, lung and ovarian tumors.• Statistical support for scientists in translational medicine and research: Design analysis workflows for single cell Fluidigm and Luminex experiments. Customized analysis and statistical consulting.• Contributing Author on the following posters presented at ASCO and ESMO:"Phase 1b study of WNT inhibitor vantictumab with nab-paclitaxel and gencitabine in patients with previously untreated stage IV pancreatic cancer.""Phase 1b study of WNT inhibitor vantictumab with paclitaxel in patients with 1st - to 3rd line metastatic HER2-negative breast cancer.""Phase 1b study of WNT inhibitor ipafricept with nab-paclitaxel and gencitabine in patients with previously untreated stage IV pancreatic cancer.""WNT pathway antagonist ipafricept inhibits tumor growth and reduces tumor initiating cell frequency in ovarian patient-derived xenograft models."

• Instructor of record for three undergraduate classes: Quantitative Reasoning, Algebra for Pre-Calculus, and Introduction to Statistics.• Responsible for preparing and delivering lectures as well as student progress assessment for two classes a semester of approximately 30 students.• Statistical consultation for other departments.

• Wrote scripts to analyze qPCR data.• Wrote R packages to streamline qPCR analysis.• Review and document previously created R scripts.• Designed and wrote web-based php application to query a mySQL database then analyze and plot the results.

• Create python scripts to perform structure-structure protein alignments on a Linux cluster.• Create python scripts to automate Linux cluster and SQL database use.